The company states: "The Q1 2023 total revenue forecast reflects management’s expectation for revenues and profitability in 2023 to be weighted towards the second half of the year."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EBS:
- Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
- Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
- Emergent announces FDA advisory committees vote in favor of OTC Narcan
- FDA Joint Committee Meeting
- Emergent Surges after Selling its Travel Health Business for $380 Million
